Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Dabigatran Etexilate in Healthy Japanese and Caucasian Males
NCT02171468Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2006
- Primary completion
- Jul 2006
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of dabigatran in thromboembolism (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Occurrence of adverse events up to 10 days, Changes in QT(c) intervals up to 7 days and 2 more. Started May 2006; status: completed.
02
Drugs
dabigatran
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02171468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171468.